People · Operator

Alon Pinkas

Named in public records as an officer, director or promoter · active 2012–2014 · Biotechnology

1
Companies
3
Filings
$12.3M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Brainstorm Cell Therapeutics Inc.BiotechnologySeries A$12.3M$379.6M2012
Operator network

Alon Pinkas at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Chen Schor · 4 companies · 1 sharedChen SchorIrit Arbel · 2 companies · 1 sharedIrit ArbelRobert Shorr · 2 companies · 1 sharedRobert ShorrAbraham Israeli · 1 companies · 1 sharedAbraham IsraeliAdrian S. Harel · 1 companies · 1 sharedAdrian S. HarelAnthony S. Fiorino · 1 companies · 1 sharedAnthony S. FiorinoChaim Lebovits · 1 companies · 1 sharedChaim LebovitsChaim S. Lebovits · 1 companies · 1 sharedChaim S. LebovitsLiat Sossover · 1 companies · 1 sharedLiat SossoverMalcolm S. Taub · 1 companies · 1 sharedMalcolm S. TaubMalcolm Taub · 1 companies · 1 sharedMalcolm TaubMordechai Friedman · 1 companies · 1 sharedMordechai FriedmanMordechai S. Friedman · 1 companies · 1 sharedMordechai S. Frie…Uri S. Yablonka · 1 companies · 1 sharedUri S. YablonkaBrainstorm Cell Therapeutics Inc. · $12.3M raisedBrainstorm Cell Thera…Alon PinkasAP
Alon Pinkas Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Alon Pinkas on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Chen Schor14
Irit Arbel12
Robert Shorr12
Chaim S. Lebovits11
Anthony S. Fiorino11
Mordechai S. Friedman11
Uri S. Yablonka11
Malcolm Taub11
Chaim Lebovits11
Mordechai Friedman11
Adrian S. Harel11
Abraham Israeli11
Malcolm S. Taub11
Liat Sossover11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.